Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stromal cells, ex vivo cultured
- Development stage
- Phase 3
- Lead developer
- medac
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Mesenchymal stromal cells, ex vivo cultured (specifically the product Obnitix developed by Medac), is an allogeneic cell therapy consisting of bone marrow-derived mesenchymal stromal cells (MSCs) that have been expanded in vitro. It is primarily indicated for the treatment of steroid-refractory acute graft-versus-host disease (aGvHD). The therapeutic effect is mediated through the immunomodulatory properties of MSCs, which involve the secretion of various anti-inflammatory factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and transforming growth factor-beta (TGF-β). These factors collectively suppress the activation and proliferation of alloreactive T cells and other immune effectors, while promoting the induction of regulatory T cells (Tregs), thereby reducing the systemic inflammatory response and tissue damage associated with GvHD.
- Brand names
- Obnitix
- Other names
- mesenchymal stromal cells, ex vivo culturedbone marrow-derived mesenchymal stromal cellsex vivo expanded mesenchymal stromal cells
Beyond the preview
Go deeper on mesenchymal stromal cells, ex vivo cultured.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stromal cells, ex vivo cultured.